We use cookies on our website. Carry on browsing if you’re happy with this or find out more

About us

:

We are a therapeutic antibody company

Based in Cambridge, UK, we are a clinical-stage biopharmaceutical company developing a deep pipeline of novel human antibody-based therapies in a broad range of indications. Our unique platforms generate a vast repertoire of fully-human, species cross-reactive and affinity-matured antibodies against challenging targets.

Working with partners since 2010

With investment totalling $220m, we are using our antibody platforms to realise new opportunities in therapeutic antibodies and vaccine development.

Our history

From the Wellcome Trust Sanger Institute’s first spin-out to a leading therapeutic antibody company.

Learn more

Our vision

Our vision is to be a global biopharmaceutical company, driving the development of therapeutic human antibodies.

Learn more

Our partnerships

We work in partnerships, enhancing each other’s complementary skills to rapidly discover and test validated lead prospects.

Learn more

World leading partners

  • Bill & Melinda Gates Foundation
  • Heptares Therapeutics
  • Novo Nordisk
  • LifeArc
View our partnerships

Our intellectual power

80
%
have at least a Bachelor’s degree
37
%
have a PhD
20
countries represented

Led by a team with world-class antibody development experience, we recruit key people to all parts of Kymab with proven skills in genetics, genomics, clinical medicine, drug development, antibody therapeutics, disease studies, business development and financial control.

Kymab Group Ltd: The Bennet Building (B930), Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT. Registered in England. Company registration number 10414057.

Kymab has one of the most comprehensive transgenic technologies.

Trevor Mundel, Global Health President, Bill & Melinda Gates Foundation: Press Release, 16 May 2014